Q1 EPS Estimates for Globus Medical Lowered by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Investment analysts at Roth Capital decreased their Q1 2025 EPS estimates for Globus Medical in a research note issued to investors on Monday, December 16th. Roth Capital analyst J. Wittes now expects that the medical device company will post earnings per share of $0.75 for the quarter, down from their previous estimate of $0.80. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share. Roth Capital also issued estimates for Globus Medical’s Q2 2025 earnings at $0.84 EPS, Q3 2025 earnings at $0.88 EPS, FY2025 earnings at $3.44 EPS, FY2026 earnings at $4.30 EPS and FY2027 earnings at $4.76 EPS.

Other research analysts have also recently issued reports about the stock. Stifel Nicolaus lifted their target price on shares of Globus Medical from $80.00 to $92.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Morgan Stanley raised shares of Globus Medical from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $83.00 to $100.00 in a research report on Monday, December 2nd. Bank of America upped their price objective on Globus Medical from $55.00 to $80.00 and gave the company an “underperform” rating in a research report on Wednesday, November 6th. Royal Bank of Canada lifted their target price on Globus Medical from $80.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group upped their price target on Globus Medical from $85.00 to $92.00 and gave the company a “buy” rating in a report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.55.

Globus Medical Price Performance

GMED opened at $81.94 on Wednesday. The firm has a market cap of $11.16 billion, a PE ratio of 122.30, a P/E/G ratio of 1.99 and a beta of 1.19. The stock has a 50-day moving average price of $79.78 and a 200-day moving average price of $73.23. Globus Medical has a 1 year low of $49.33 and a 1 year high of $87.22.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.18. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. The business had revenue of $625.71 million during the quarter, compared to analysts’ expectations of $604.69 million. During the same quarter in the previous year, the business earned $0.57 earnings per share. The firm’s quarterly revenue was up 63.1% compared to the same quarter last year.

Insider Buying and Selling at Globus Medical

In related news, Director David D. Davidar sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the completion of the transaction, the director now directly owns 536,275 shares in the company, valued at approximately $40,242,076. The trade was a 5.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Kelly Huller sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $87.00, for a total transaction of $217,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 97,500 shares of company stock valued at $7,674,950. Insiders own 18.54% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

Several institutional investors and hedge funds have recently modified their holdings of GMED. V Square Quantitative Management LLC purchased a new position in Globus Medical during the third quarter valued at $27,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of Globus Medical during the second quarter valued at about $33,000. Quarry LP increased its holdings in shares of Globus Medical by 698.4% in the third quarter. Quarry LP now owns 495 shares of the medical device company’s stock worth $35,000 after purchasing an additional 433 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Globus Medical by 230.5% in the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock worth $39,000 after buying an additional 385 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new position in Globus Medical during the 2nd quarter valued at approximately $52,000. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.